Skip Navigation and Go To Content

Clinical Trials Resource Center

Ongoing Trials at UTHealth

DERMATOLOGY

GASTROENTEROLOGY

HEPATOLOGY

HEART & VASCULAR

HEMODIALYSIS

  • Heparin-bonded versus Non-heparin-bonded Polytetrafluroethylene Hemodialysis Access Grafts
    Coordinator Name: Samuel Leake
    E-mail: Samuel.S.Leake@uth.tmc.edu 
    Phone: 713-486-5120
    Principal Investigator: Kristofer Charlton-Ouw, MD
    for more information - clinicaltrials.gov

HIV

HYPERTENSION

  • Determination of Genetics in Childhood Onset Hypertension 
    Coordinator Name: Josephine Turner
    Phone: 713-704-4137
    Email: Josephine.Turner@uth.tmc.edu
    Coordinator Name: Cary Warner
    Phone Number: 713-704-3743
    Principal Investigator: Syed Hashmi, MD, MPH, PhD

NEPHROLOGY

  • A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)- Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine
    Principal Investigator: Dia R. Waguespack, MD
    Study Coordinator: Iram Abbasi
    Email: RenalResearch@uth.tmc.edu
    Phone: 713-500-6820
    Main Inclusion Criteria: Aged at least 18 years, with newly-diagnosed or relapsed AAV where treatment with Cyclophosphamide or rituximab is needed
  • A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anemia and non-dialysis-dependent chronic kidney disease
    Principal Investigator: Dia R. Waguespack, MD
    Study Coordinator: Iram Abbasi
    Email: RenalResearch@uth.tmc.edu
    Phone: 713-500-6820
    Main Inclusion Criteria: >18 years of age
  • A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease
    Principal Investigator: Dia R. Waguespack, MD
    Study Coordinator: Iram Abbasi
    Email: RenalResearch@uth.tmc.edu
    Phone: 713-500-6820
    Main Inclusion Criteria: >18 years of age
  • A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis
    Principal Investigator: Dia R. Waguespack, MD
    Study Coordinator: Iram Abbasi
    Email: RenalResearch@uth.tmc.edu
    Phone: 713-500-6820
    Main Inclusion Criteria: 18 to 75 years of age
  • Pathway Exploration and Analysis in Renal Lupus (PEARL) – Phase 2
    Principal Investigator: Dia R. Waguespack, MD
    Study Coordinator: Iram Abbasi
    Email: RenalResearch@uth.tmc.edu
    Phone: 713-500-6820
    Main Inclusion Criteria: >18 years of age

NEUROLOGY

  • Aseptic Meningoencephalitis in Adults 
    Coordinator Name: Monika Ruscheinsky 
    E-mail: monika.ruscheinsky@uth.tmc.edu   
    Phone: 713-704-0825 
    Principal Investigator: Rodrigo Hasbun, MD, MPH
  • Relapsing Remitting Multiple Sclerosis Study
    EVOLVE II ALK8700-A302: A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
    Study Coordinator: Jim Jemelka
    E-mail: James.R.Jemelka@uth.tmc.edu
    Phone: 713-500-7045
    Principal Investigator: Flavia M. Nelson, MD

    Target Population: People with relapsing remitting multiple sclerosis

  • Multiple Sclerosis Study
    NARCRMS (North American Registry for Care and Registry for Multiple Sclerosis): Towards the development of a National Longitudinal Database in Multiple Sclerosis. Under the auspices of the Consortium of MS Centers (CMSC)
    Study Coordinator: Jim Jemelka
    E-mail: James.R.Jemelka@uth.tmc.edu
    Phone: 713-500-7045
    Principal Investigator: Flavia M. Nelson, MD

    Target Population: People with multiple sclerosis within the first 10 years of diagnosis
  • Relapsing Multiple Sclerosis Study
    LEM-COG Trial: A 24-Month Observational Study to Evaluate Neurocognitive Function and Safety in Patients with Relapsing Multiple Sclerosis Who are Initiating LEMTRADA® (Alemtuzamab) Treatment in Routine Clinical Practice
    Study Coordinator: Jim Jemelka
    E-mail: James.R.Jemelka@uth.tmc.edu
    Phone: 713-500-7045
    Principal Investigator: John Lincoln, MD, PhD

    Target Population: People with relapsing multiple sclerosis who are initiating Lemtrada® (alemtuzamab) treatment in routine clinical practice

  • Multiple Sclerosis Study
    Lower extremity exoskeleton to promote walking in persons with multiple sclerosis
    Study Coordinator: Jim Jemelka
    E-mail: James.R.Jemelka@uth.tmc.edu
    Phone: 713-500-7045
    Principal Investigators: Shuo-Hsiu (James) Chang, PT, PhD; John Lincoln, MD, PhD

    Target Population: People with multiple sclerosis who are willing to complete 5 training sessions each week for 3 weeks at the Texas Institute of Rehabilitation and Research (TIRR) at the Texas Medical Center

PEDIATRIC SURGERY

PSYCHIATRY

PULMONARY

REPRODUCTIVE

 

SCLERODERMA

SLEEP

SUBSTANCE ABUSE

  • Cocaine Use Treatment Research Studies
    Cognitive-enhancing DA Medications for Cocaine Dependence
    Coordinator: Jessica Vincent
    E-mail: Jessica.N.Vincent@uth.tmc.edu
    Phone: 713-486-2803
    Principal Investigator: Joy M. Schmitz, PhD
  • PTSD & Substance Use Treatment Study
    Trial of a Novel Treatment for Posttraumatic Stress and Substance Dependence
    Coordinator: Jessica Vincent
    E-mail: Jessica.N.Vincent@uth.tmc.edu
    Phone: 713-486-2803
    Principal Investigator: Anka Vujanovic, PhD

WEIGHT LOSS

ADDITIONAL RESOURCES

CLINICAL RESEARCH UNITS (CRU) | BERD | REDCap
COMMITTEE FOR THE PROTECTION OF HUMAN SUBJECTS | ANIMAL RESEARCH | ENVIRONMENTAL HEALTH & SAFETY | CORE LABORATORIES | SPONSORED PROJECTS TECHNOLOGY MANAGEMENT
OFFICE OF RESEARCH 

Center for Clinical and Translational Sciences

Clinical Trials Resource Center (CTRC)
7000 Fannin Street, Suite 795

Houston, Texas 77030
phone 713-500-3622
fax 713-500-0334
clinicaltrials@uth.tmc.edu

last modified October, 2013
Copyright © 2012
How can we improve this site?